Bioventus Inc. Class A (BVS) Peer Comparison
$13.40
$-0.17
(-1.22%)
As on 14-Oct-2026 13:30EDT
Market cap
$892 Mln
Revenue (TTM)
$582 Mln
P/E Ratio
16.8
P/B Ratio
4.1
Div. Yield
0 %
Edit
| Bioventus Inc. Class A (BVS) | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
892 | 12,507 | 10,508 | 11,040 | 10,599 |
Revenue ($ Mln) |
582 | 1,505 | 617 | 785 | 6,561 |
Net Profit ($ Mln) |
54.46 | 160.59 | -75.13 | 41.54 | -578.00 |
Net Margin (%) |
9.36 | 10.67 | -12.18 | 5.29 | -8.81 |
RoE (%) |
23.01 | 10.86 | -9.26 | 1.97 | -10.33 |
Price to Earnings |
16.75 | 78.01 | -- | 238.19 | -- |
Price-To-Book |
4.07 | 8.22 | 11.93 | 4.93 | 1.77 |
Income Statement ($ Mln)
| Bioventus Inc. Class A (BVS) | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
581.85 | 1,504.87 | 616.91 | 785.10 | 6,561.10 |
|
Cost of Revenue
|
186.20 | 483.98 | 184.88 | 384.30 | 4,473.00 |
|
Gross Profit
|
382.43 | 942.44 | 443.88 | 347.62 | 2,139.40 |
|
Operating Expenses
|
333.81 | 833.56 | 520.41 | 335.50 | 2,373.70 |
|
Operating Profit (EBIT)
|
61.83 | 187.34 | -88.38 | 65.30 | -285.60 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
38.64 | 203.83 | -74.89 | 52.15 | -472.00 |
|
Provision for Tax
|
-22.84 | 43.24 | 0.24 | 10.61 | 106.00 |
|
Profit after Tax (Net Income)
|
54.46 | 160.59 | -75.13 | 41.54 | -578.00 |
|
Minority Interest
|
-7.01 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 93.19 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Bioventus Inc. Class A (BVS) | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
228.31 | 1,530.77 | 825.55 | 2,112.03 | 5,630.20 |
|
Minority Interest
|
-7.01 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
243.48 | 210.18 | 86.01 | 705.49 | 4,583.70 |
|
Current Liabilities
|
152.45 | 233.78 | 118.51 | 132.66 | 1,382.00 |
|
Total Liabilities
|
683.56 | 1,826.52 | 1,041.37 | 2,949.70 | 11,794.70 |
Assets ($ Mln)
| Bioventus Inc. Class A (BVS) | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
415.82 | 630.60 | 355.40 | 1,749.63 | 9,133.70 |
|
Current Assets
|
257.53 | 1,344.12 | 674.67 | 1,200.55 | 2,462.20 |
|
Total Assets
|
683.56 | 1,826.52 | 1,041.37 | 2,949.70 | 11,794.70 |
|
Total Debt*
|
263.75 | 212.71 | 78.80 | 690.94 | 3,697.80 |
|
Net Current Assets
|
105.08 | 1,110.35 | 556.16 | 1,067.90 | 1,080.20 |
Cashflow ($ Mln)
| Bioventus Inc. Class A (BVS) | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
73.98 | 238.66 | 136.05 | 117.42 | 623.80 |
|
Cash Flow from Investing Activities
|
-3.25 | -404.59 | -13.44 | -298.47 | -130.50 |
|
Cash from Financing Activities
|
-61.44 | 26.53 | 6.80 | -15.21 | -409.40 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Bioventus Inc. Class A (BVS) | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
4.64 | 11.76 | -4.99 | 1.79 | -5.43 |
|
ROE (%)
|
23.01 | 10.86 | -9.26 | 1.97 | -10.33 |
|
ROA (%)
|
6.34 | 7.95 | -6.71 | 1.36 | -4.08 |
|
EBIT Margin (%)
|
10.06 | 13.63 | -1.34 | 9.87 | -4.47 |
|
Net Margin (%)
|
9.36 | 10.67 | -12.18 | 5.29 | -8.81 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Bioventus Inc. Class A (BVS) | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
3.14 | 17.55 | -4.28 | 16.49 | -1.57 |
|
EBIT Growth (%)
|
63.32 | 17.49 | 89.59 | 920.91 | -129.16 |
|
Net Profit Growth (%)
|
34,570.89 | 8.72 | 11.20 | 400.42 | -184.08 |
|
EPS Growth (%)
|
10,561.83 | 8.12 | 16.01 | 394.30 | -184.11 |
|
Book Value Growth (%)
|
36.99 | 17.33 | 2.26 | 2.16 | -9.82 |
Valuation Ratios
| Bioventus Inc. Class A (BVS) | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
22.56 | 68.93 | -47.60 | 189.42 | -14.68 |
|
Price / Book Value
|
2.78 | 8.58 | 2.60 | 4.40 | 1.40 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
7.79 | 53.25 | 436.68 | 50.32 | 81.94 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Bioventus Inc. Class A (BVS) | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.01 | 0.00 | 0.00 | 0.26 | 0.65 |
|
Short term debt to equity ratio
|
0.10 | 0.01 | 0.01 | 0.01 | 0.01 |
|
Current Ratio
|
1.69 | 5.75 | 5.69 | 9.05 | 1.78 |
|
Quick Ratio
|
1.17 | 3.86 | 5.25 | 7.64 | 1.18 |
|
Interest Coverage
|
2.94 | 157.91 | -24,962.33 | 1.92 | -1.64 |
Operating Efficiency Ratios
| Bioventus Inc. Class A (BVS) | Penumbra (PEN) | 10X Genomics Inc (TXG) | Repligen (RGEN) | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
23.79 | 12.65 | 8.21 | 20.09 | 17.36 |
|
Asset Turnover
|
0.68 | 0.74 | 0.55 | 0.26 | 0.46 |
|
Receivable days
|
82.20 | 46.54 | 48.40 | 72.41 | 58.79 |
|
Inventory Days
|
171.86 | 331.92 | 128.01 | 146.53 | 64.13 |
|
Payable days
|
34.05 | 26.16 | 23.54 | 29.05 | 58.13 |
|
Cash Conversion Cycle
|
220.00 | 352.30 | 152.87 | 189.88 | 64.79 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
